SmithKline Beecham
GSK Secures Broad Label Expansion for Jemperli in First-Line Endometrial Cancer
GSK, Jemperli, dostarlimab, endometrial cancer, FDA approval, chemotherapy, immuno-oncology, Keytruda, Merck
GSK Partners with Flagship Pioneering in $7 Billion Biobucks Deal for Respiratory and Immunology Research
GSK, Flagship Pioneering, biobucks, respiratory research, immunology research, pharmaceutical partnership
FDA Approves Broader Label for GSK’s Jemperli in First-Line Endometrial Cancer
FDA, GSK, Jemperli, dostarlimab-gxly, endometrial cancer, chemotherapy, carboplatin, paclitaxel, mismatch repair proficient, microsatellite stable, overall survival, progression-free survival
Pfizer Considers Facility Sale Amid GSK’s Administrative Breach in South Korea
Pfizer, facility sale, GSK, administrative breach, South Korea, pharmaceutical industry
GSK Abandons Phase 2 HPV Vaccine Due to Lack of Best-in-Class Potential
GSK, HPV vaccine, phase 2, best-in-class potential, vaccine development
GSK Partners with Flagship Pioneering to Develop 10 Novel Medicines and Vaccines
GSK, Flagship Pioneering, drug discovery, vaccines, respiratory disease, immunology, bioplatform companies, mRNA vaccines, Pfizer, biotech partnership
GSK’s Dovato Matches Efficacy of Gilead’s Biktarvy with Less Weight Gain in HIV Trial
GSK, Dovato, Gilead, Biktarvy, HIV, weight gain, Spanish trial, PASO DOBLE, ViiV Healthcare
GSK Headquarters Returns to Central London
GSK, Global Headquarters, Central London, The Earnshaw, Sustainability, Hybrid Working
Pfizer Secures Major Contract Over GSK for RSV Vaccine Supply in the UK
Pfizer, GSK, RSV vaccine, UK contract, Abrysvo, Arexvy
UK Government Selects Pfizer Over GSK to Supply RSV Vaccine Doses
Pfizer, GSK, RSV vaccine, UK government, pharmaceutical companies, vaccine supply